#1 Clinical Trials Search in Europe

H2-Receptor Antagonists

This article examines several clinical trials investigating the use of H2-Receptor Antagonists in various cancer treatments. These trials aim to evaluate the safety and efficacy of H2-Receptor Antagonists, either alone or in combination with other drugs, for different types of cancer including breast cancer, lung cancer, cervical cancer, and gastrointestinal cancers. The studies focus on patients with advanced or metastatic stages of these cancers, exploring potential new treatment options.

Table of Contents

What are H2-Receptor Antagonists?

H2-receptor antagonists, also known as H2 blockers, are a class of medications used primarily to treat conditions related to excess stomach acid[1]. These drugs work by blocking histamine receptors in the stomach, which helps reduce the production of stomach acid.

How do H2-Receptor Antagonists Work?

To understand how H2-receptor antagonists work, it’s important to know about histamine and its role in the body. Histamine is a chemical that triggers the release of stomach acid. H2-receptor antagonists block the histamine receptors on the cells in the stomach that produce acid. By doing this, they reduce the amount of acid produced, which can help alleviate symptoms associated with excess stomach acid[2].

Medical Uses of H2-Receptor Antagonists

H2-receptor antagonists are commonly used to treat several conditions related to excess stomach acid, including:

  • Gastroesophageal reflux disease (GERD): A condition where stomach acid frequently flows back into the esophagus
  • Peptic ulcers: Sores that develop on the lining of the stomach or small intestine
  • Dyspepsia: A term for stomach discomfort, which can include symptoms like nausea, bloating, and burping
  • Zollinger-Ellison syndrome: A rare condition that causes tumors in the pancreas and duodenum, leading to increased stomach acid production

These medications can provide relief from symptoms such as heartburn, acid indigestion, and stomach pain[3].

Administration and Dosage

H2-receptor antagonists are available in various forms, including tablets, liquids, and injections. The most common route of administration is oral, but in some cases, they may be given intravenously in a hospital setting[4]. The dosage and frequency of administration depend on the specific condition being treated and the individual patient’s needs. It’s crucial to follow your doctor’s instructions or the guidance provided on the medication label.

Potential Side Effects

While H2-receptor antagonists are generally well-tolerated, like all medications, they can cause side effects in some people. Common side effects may include:

  • Headache
  • Dizziness
  • Diarrhea or constipation
  • Nausea or vomiting
  • Fatigue

More serious side effects are rare but can include changes in heart rhythm, confusion (especially in older adults), and liver problems. If you experience any unusual or severe side effects, it’s important to contact your healthcare provider immediately[5].

Ongoing Research and Clinical Trials

While H2-receptor antagonists have been used for decades to treat acid-related conditions, ongoing research is exploring their potential in other areas of medicine. Several clinical trials are currently investigating the use of H2-receptor antagonists in combination with other drugs for various types of cancer[6].

For example, studies are looking at the combination of H2-receptor antagonists with immunotherapy drugs like pembrolizumab in treating cancers such as:

  • Breast cancer
  • Non-small cell lung cancer (NSCLC)
  • Gastric and gastroesophageal cancers
  • Cervical cancer
  • Colorectal cancer
  • Pancreatic cancer
  • Biliary tract cancer

These studies aim to evaluate the safety and efficacy of these combination therapies in improving outcomes for cancer patients. However, it’s important to note that these are still in the research phase, and more evidence is needed before any conclusions can be drawn about their effectiveness in cancer treatment[7].

Conclusion

H2-receptor antagonists play a crucial role in managing conditions related to excess stomach acid. They offer relief for millions of people suffering from GERD, ulcers, and other gastrointestinal issues. While they are primarily used for acid-related conditions, ongoing research is exploring their potential in other areas of medicine, including cancer treatment. As with any medication, it’s important to use H2-receptor antagonists under the guidance of a healthcare professional and to be aware of potential side effects. If you have any concerns or questions about H2-receptor antagonists, don’t hesitate to discuss them with your doctor.

Cancer Type Trial Phase Treatment Approach Primary Endpoints
Breast Cancer Phase III H2-Receptor Antagonists with pembrolizumab Progression-Free Survival, Overall Survival
Non-Small Cell Lung Cancer Phase III H2-Receptor Antagonists as maintenance therapy Disease-Free Survival, Overall Survival
Cervical Cancer Phase III H2-Receptor Antagonists monotherapy Objective Response Rate, Overall Survival
Gastrointestinal Cancers Phase I/II H2-Receptor Antagonists alone or in combination Safety, Objective Response Rate
Squamous Non-Small Cell Lung Cancer Phase III H2-Receptor Antagonists as maintenance therapy Overall Survival

FAQ

  • What are H2-Receptor Antagonists? H2-Receptor Antagonists are a class of drugs that block histamine receptors in the stomach. In these clinical trials, they are being studied for their potential anti-cancer effects when used alone or in combination with other cancer treatments.
  • What types of cancer are being studied with H2-Receptor Antagonists? The clinical trials are investigating H2-Receptor Antagonists in various cancers including breast cancer, lung cancer, cervical cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer.
  • How are H2-Receptor Antagonists being used in these trials? H2-Receptor Antagonists are being tested as monotherapy (used alone) and in combination with other cancer drugs like pembrolizumab. They are being studied in different stages of treatment, including as maintenance therapy after initial treatment.
  • What are the main goals of these clinical trials? The main objectives of these trials are to evaluate the safety and efficacy of H2-Receptor Antagonists in cancer treatment. They aim to measure outcomes such as overall survival, progression-free survival, and objective response rate.
  • Who can participate in these clinical trials? Eligibility varies by trial, but generally includes adult patients with specific types and stages of cancer who have received certain prior treatments. Each trial has specific inclusion and exclusion criteria based on factors like cancer type, stage, and previous treatments.

Ongoing Clinical Trials on H2-Receptor Antagonists

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia France Germany Hungary Ireland +4

  • Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +10

  • Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9

  • Study on the Safety and Effectiveness of MK-2870 Alone or with Other Drugs for Patients with Colorectal, Pancreatic, and Biliary Tract Cancers

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +5

  • Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Italy Poland +1

  • Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Hungary Italy Romania Spain

Glossary

  • H2-Receptor Antagonists: A class of drugs that block histamine receptors in the stomach, being studied for potential anti-cancer effects.
  • Pembrolizumab: An immunotherapy drug that helps the immune system detect and fight cancer cells.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria In Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Blinded Independent Central Review (BICR): A method where treatment responses are assessed by independent experts who don't know which treatment a patient received.
  • Quality of Life (QoL): A measure of a patient's general well-being and ability to enjoy normal life activities during treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. http://clinicaltrials.eu/trial/study-comparing-mk-2870-and-pembrolizumab-with-chemotherapy-for-patients-with-advanced-hormone-receptor-positive-breast-cancer/
  2. http://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-and-pembrolizumab-for-patients-with-triple-negative-breast-cancer-post-surgery/
  3. http://clinicaltrials.eu/trial/study-of-mk-2870-for-patients-with-advanced-or-metastatic-stomach-cancer-comparing-its-effects-to-a-drug-combination/
  4. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-mk-2870-for-patients-with-resectable-stage-ii-iiib-nsclc-after-surgery/
  5. http://clinicaltrials.eu/trial/study-of-mk-2870-for-patients-with-recurrent-or-metastatic-cervical-cancer-after-previous-treatments/
  6. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mk-2870-alone-or-with-other-drugs-for-patients-with-colorectal-pancreatic-and-biliary-tract-cancers/
  7. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-mk-2870-for-patients-with-metastatic-squamous-non-small-cell-lung-cancer/